Close Menu

Horizon Discovery

The gene editing and gene modulation technologies firm attributed the decline to the impact of the SARS-CoV-2 pandemic on its research reagents business.

The Cambridge, UK-based firm saw double-digit growth in its screening business and declines in its bioproduction and diagnostics businesses.

The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.

The company said revenue growth during the year was driven by performance in its research reagents and screening business units.

The company, which recently signed a licensing agreement with Horizon Discovery, just raised $45 million in a Series B financing round.

Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.

Horizon also said it will provide access to the technology to business partners for the development of more effective multi-gene knockout cell therapy programs.

In December, the companies agreed to develop CRISPR tools with the aim of generating new engineered cell lines for the biopharmaceutical industry.

The companies will identify and optimize novel CRISPR proteins owned by Mammoth, and then license those proteins to Horizon for use in engineered cell lines.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.